New Approved Indication for Ibrutinib


    loading  Checking for direct PDF access through Ovid

Abstract

Ibrutinib (Imbruvica) has been approved to treat chronic lymphocytic leukemia in patients who've received treatment at least once with other drug therapy.Common adverse effects are numerous and include thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory tract infection, fatigue, musculoskeletal pain, rash, fever, constipation, peripheral edema, arthralgia, nausea, stomatitis, sinusitis, and dizziness.

    loading  Loading Related Articles